REAL Patient RESULTS

PROGRESS YOU CAN SEE

SERNIVO Spray demonstrated noticeable results in multiple patient types.a

After 2 weeks of treatment, most subjects’ IGA grade changed from “moderate” to “mild.”1,b

TREATMENT SATISFACTION

Patients reported significant improvements in Treatment Satisfaction Questionnaire for Medication (TSQM) by Day 14 in an open-label study (n=45)1,c,d

Convenience

Tolerability

Effectiveness

Global Satisfaction

cResults of an open-label, multicenter study (n=45). Co-primary endpoint for study included change in TSQM from baseline at Day 14.
dEvaluated using TSQM version 2.0, an 11-item instrument measuring 4 dimensions of treatment satisfaction (Effectiveness, Side Effects, Convenience, and Overall Satisfaction) that yields a total score ranging from 0 (extremely dissatisfied) to 100 (extremely satisfied).2

IMPROVEMENT IN QUALITY OF LIFE

Results show a continued improvement of DLQI scores over 4 weeks of treatment in an open-label study (n=45)e

Improved QoL Ratings Reflected by Reduction in DLQI Scores

*Primary endpoint.
eResults of an open-label, multicenter study (n=45). The Dermatology Life Quality Index (DLQI) is a validated, 10-item questionnaire that assesses dermatology-specific quality of life (QoL),3,4 and yields a total score of 0 (best QoL) to 30 (worst QoL).5 Thus, a decrease in DLQI score indicates improvement.

IMPORTANT SAFETY INFORMATION

SERNIVO Spray can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Systemic effects of topical corticosteroids may also manifest as Cushing’s syndrome, hyperglycemia or unmasking of latent diabetes mellitus, and glucosuria. These events are rare and generally occur after prolonged exposure to larger than recommended doses, particularly with high-potency topical corticosteroids. Do not use if atrophy is present at the treatment site. Do not use with occlusive dressings. Avoid use on the face, scalp, axilla, groin or other intertriginous areas. Use of SERNIVO Spray is not recommended in pediatric patients as they are more susceptible to systemic toxicity. Allergic contact dermatitis may occur. The most common adverse reactions (≥1%) were application site pruritus, burning and/or stinging, pain, and atrophy. Local reactions and skin atrophy are more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids. These are not all the possible side effects of SERNIVO Spray.
Please refer to Full Prescribing Information.

INDICATION AND USAGE

SERNIVO Spray is indicated for the treatment of mild-to-moderate plaque psoriasis in patients 18 years of age or older.

To report SUSPECTED SIDE EFFECTS, call Promius Pharma at 1-888-966-8766 or contact the FDA at
1-800-FDA-1088.

References: 1. Fowler JF, Del Rosso JQ, Pakunlu RI, Sidgiddi S. Treatment satisfaction, product perception, and quality of life in plaque psoriasis patients using betamethasone dipropionate spray 0.05%. J Clin Aesthet Dermatol. 2017;10(11):13-18. 2. QuintilesIMS™. Treatment Satisfaction Questionnaire for Medication (TSQM). Available at: http://www.quintiles.com/landing-pages/ treatment-satisfaction-questionnaire-formedication-tsqm. Accessed April 19, 2017. 3. Cardiff University Department of Dermatology. Dermatology Quality of Life Index (DLQI). Available at: http://sites.cardiff.ac.uk/ dermatology/quality-of-life/dermatologyquality-of-life-index-dlqi/. Accessed April 19, 2017. 4. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. 5. Murray CS, Rees JL. How robust are the Dermatology Life Quality Index and other self-reported subjective symptom scores when exposed to a range of experimental biases?. Acta Derm Venereol. 2010;90(1):34–38.

Eligibility Rules

Patient Instructions: Redeem this coupon ONLY when accompanied by a valid presciption for SERNIVO® (betamethasone dipropionate) Spray, 0.05%. Commercially insured patients pay $0 for their prescription. Maximum reimbursement limits apply. This card must be presented at the time of fill for instant savings. Offer is good for commercially insured patients only. This coupon is good for up to 12 uses and is not transferable.
Please consult Full Prescribing Information for SERNIVO. Not valid for cash-paying patients or patients reimbursed by federal healthcare programs, including Medicare, Medicaid, Tri Care, the Department of Veterans Affairs, state maternal and child health block grant programs under 42 U.S.C. 701 et. seq. state social service block grant programs under 42 U.S.C. section 1397 et. seq. or any other similar federal or state healthcare program. Void where prohibited by law, taxed or restricted. Void outside the United States. Void for residents of Massachusetts. Patient is responsible for reporting receipt of card program rewards to any private insurer that pays for or reimburses any part of the prescriptions filled with this card. Void if reproduced. It is illegal for any person to sell, purchase, or trade, or offer to sell, purchase or trade, or to counterfeit this card. Offer expires 12 months after initial use. Promius Pharma reserves the right to rescind, revoke or amend this offer at any time without notice.  

Download Co-Pay Card

THANK YOU

Thank you for signing up to receive news and information about SERNIVO. To fill out a sample request form, click the button below.

Download Sample Form Download Co-Pay Card

IMPORTANT SAFETY INFORMATION
SERNIVO Spray can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Systemic effects of topical corticosteroids may also manifest as Cushing's syndrome, hyperglycemia or unmasking of latent diabetes mellitus, and glucosuria. These events are rare and generally occur after prolonged exposure to larger than recommended doses, particularly with high-poten cy topical corticosteroids..